Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening
Sponsor: Jerry A. Nick, M.D.
Summary
This is a prospective, single-center, nonrandomized observational study to investigate the utility of urine lipoarabinomannan (LAM) as a test to identify individuals at very low risk for having a sputum culture positive for Nontuberculous Mycobacteria (NTM). The study is designed to evaluate if a urine test can eliminate the need for obtaining a sputum specimen to screen for NTM in individuals with Cystic Fibrosis (CF). The participants will be asked to provide 3 urine samples either in person or by mail over approximately 3 years. The 3 urine sample requests will be timed to coincide with their usual clinical care and routine sputum collection.
Official title: Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening (PAINLESS Trial)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
220
Start Date
2020-12-10
Completion Date
2026-05-01
Last Updated
2025-05-23
Healthy Volunteers
No
Conditions
Interventions
urine lipoarabinomannan (LAM)
Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
Locations (1)
National Jewish Health
Denver, Colorado, United States